Andrew Wei

76PUBLICATIONS
419CO-AUTHORS
Regenerative medicine (incl. stem cells)Medical virologyPredictive and prognostic markersHaematologyMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (76)

|Jul 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

|Jun 04, 2026
ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

|Feb 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos

|Dec 18, 2025
Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.

Alice J Liu, Emily Batterham, Rithin Nedumannil

|Dec 15, 2025
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

Jacqueline Cloos, Peter J M Valk, Christian Thiede

|Nov 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos

Pageof 13

Frequent Collaborators

20 joint publications

Ing Soo Tiong

14 joint publications

Courtney D DiNardo

12 joint publications

Pau Montesinos

10 joint publications

Sun Loo